Crohn's Disease News and Research

Latest Crohn's Disease News and Research

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

24 Feb 2014

New research finds direct connection between acupuncture and processes that alleviate sepsis

When acupuncture first became popular in the western hemisphere it had its doubters. It still does. But over time, through detailed observation, scientists have produced real evidence that ancient Chinese practitioners of the medical arts were onto something.

23 Feb 2014

Researchers propose new treatment to prevent mucositis in cancer patients

Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation - has been achieved by an international team of researchers from the US and Israel headed by scientists at the Hebrew University of Jerusalem.

20 Feb 2014

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has awarded Soligenix a Small Business Innovation Research grant to support further preclinical development of SGX943 as a treatment for melioidosis.

14 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

A comprehensive analysis of patient telephone records at an inflammatory bowel disease (IBD) clinic revealed that 15 percent of patients account for half of all calls to the clinic. Forty-two percent of frequent-caller patients also were seen in the emergency department or hospitalized within the following year.

10 Feb 2014

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

3 Feb 2014

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine).

30 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Study shows high-fiber diet reduces risk of colon problems

Scientists have more reasons for you to eat fiber and not abuse antibiotics.

17 Jan 2014

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Researchers from the La Jolla Institute for Allergy and Immunology have revealed a critical player in the cellular interactions leading to eczema - a chronic inflammatory skin condition affecting more than 14 million U.S. children and adults.

10 Jan 2014

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April.

9 Jan 2014

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn’s disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids.

9 Jan 2014

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life.

9 Jan 2014

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease.

7 Jan 2014

How Obamacare coverage is shaking out

Even with the health law's insurance options, consumers struggling with chronic diseases may still face such high out-of-pocket costs on some plans that they could have trouble staying out of debt, reports the Associated Press. Meanwhile, several major drugstore chains are offering to fill prescriptions for those who enrolled in new health plans but don't have ID numbers yet.

6 Jan 2014

First Edition: January 6, 2014

Today's headlines include reports about how the health law fits into the Capitol Hill agenda for the year ahead.

6 Jan 2014

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food & Drug Administration has extended the Prescription Drug User Fee Act Priority Review action date for the ulcerative colitis indication of Takeda's investigational biologic, vedolizumab.

24 Dec 2013

Six common diseases arise from DNA changes, finds new research

Many rare disorders are caused by gene mutation, like sickle cell anemia. Yet until now the underlying genetic cause of more common conditions - for example, rheumatoid arthritis - has evaded scientists for years.

22 Dec 2013

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

New research finds direct connection between acupuncture and processes that alleviate sepsis

Researchers propose new treatment to prevent mucositis in cancer patients

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Alvogen launches Inflectra into Central and Eastern Europe

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Telephone communication in IBD care helps to identify patients at risk of high-cost medical interventions

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Altheus Therapeutics receives patent for oral combination therapy for treating inflammatory bowel disease

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Study shows high-fiber diet reduces risk of colon problems

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

How Obamacare coverage is shaking out

First Edition: January 6, 2014

FDA extends PDUFA Priority Review action date for UC indication of Takeda's vedolizumab

Six common diseases arise from DNA changes, finds new research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in